Corporate Member Update: Merck

Merck would like to inform you that the FDA has granted full approval to KEYTRUDA® (pembrolizumab) Injection
100 mg, in combination with enfortumab vedotin, and expanded the indication to:

• treatment of adult patients with locally advanced or metastatic urothelial cancer.

The combination initially received accelerated approval in April 2023 for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.

To read the full release, please click here!